In vivo effect of I'm-Yunity™ on hepatic cytochrome P450 3A4

Journal of Herbal Pharmacotherapy

Volumn 7, Issue 1, 2007, Pages 39-56

  Nicandro, Jean Paul A ^a   Tsourounis, Candy ^a   Frassetto, Lynda ^b   Guglielmo, B Joseph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coriolus versicolor; CYP3A4; Drug interactions; Erythromycin breath test; I'm Yunity; PSP

Indexed keywords

CORIOLUS VERSICOLOR EXTRACT; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; I M YUNITY; PLANT EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORIOLUS VERSICOLOR; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HERB DRUG INTERACTION; HUMAN; IN VIVO STUDY; INSOMNIA; MALE; MUSHROOM; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; THIRST; TREATMENT DURATION; VIVID DREAM; XEROSTOMIA;

ADULT; BIOLOGICAL TRANSPORT; BREATH TESTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, CHINESE HERBAL; ERYTHROMYCIN; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS;

EID: 34347379283     PISSN: 15228940     EISSN: 15229106     Source Type: Journal    
DOI: 10.1300/J157v07n01_04     Document Type: Article

References (27)

1. Cui J, Chisti Y. Polysaccharopeptides of Coriolus versicolor. Physiological activity, uses, and production. Biotechnol Adv. 2003; 21:109-22.
2. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton J. Interactions of herbs with cytochrome P450. Drug Metab Rev. 2003; 35:35-98.
3. Cummins CL, Wu C, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther. 2002; 72:474-89.
4. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998; 38:389-430.
5. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Effect of St John's Wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. J Amer Med Assoc. 2003; 11:1500-4.
6. Ng TB. A review of research on the protein-bound polysaccharide from the mushroom Coriolus versicolor. Gen Pharmac. 1998; 30:1-4.
7. Dietary Supplement Health and Education Act of 1994 [www.fda.gov/opacom/ laws/dshea.html].
8. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4:171-84.
9. Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. The erythromycin breath test for the prediction of drug clearance. Clin Pharmacokinet. 2001; 40: 151-8.
10. Metabolic Solutions, Inc. Erythromycin breath test (package insert). Nashua, NH, 2004.
11. Chiou WL, Jeong HY, Wu TC, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin Pharmacol Ther. 2001; 70:305-10.
12. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther. 2000; 68:356-66.
13. De Vane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, et al. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharm. 2004; 24:4-10.
14. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL, Bhat K, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13:595-606.
15. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol. 2001; 51:591-600.
16. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002; 72:1-9.
17. Chu KK, Ho SS, Chow AH. Coriolus versicolor: A medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol. 2002; 42:976-84.
18. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzellan PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest. 1989; 83:688-97.
19. Wagner D. CYP3A4 and the EBT (letter). Clin Pharmacol Ther. 1998; 64:129.
20. Rivory LP, Watkin PB. Erythromycin breath test. Clin Pharmacol Ther. 2001; 70:395-9.
21. Kivisto KT, Kroemer HK. Use of prove drugs as predictors of drug metabolism in humans. J Clin Pharmacol. 1997; 37:40-8S.
22. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther. 1992; 52:265-73.
23. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between oral erythromycin breath test and rifampin. Clin Pharmacol Ther. 2002; 72:524-35.
24. 14C-N-methyl] erythromycin breath test in healthy volunteers. J Clin Pharmacol. 1998; 38:492-5.
25. McCrea J. Prueksaritanont T. Gertz BJ, Carides A, Gillen L, Antonello S, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol. 1999; 39:1212-20.
26. Sun H, Huang Y, Frassetto L, Benet LZ. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos. 2004; 32:1239-46.
27. Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004; 5:273-82.